CZP ITT population (N=492)
Wk 24 
HAQ-DI, mean (SD)
1.6 (0.6) 1.7 (0.5) 1.6 (0.6) 1.6 (0.6) 1.6 (0.7)
DAS28(ESR), median (min, max)
6.8 (5, 9) 7.1 (5, 9) 6.6 (5, 9) 6.9 (5, 9) 6.4 (5, 8)
CZP, certolizumab pegol; DAS28, Disease activity score 28; HAQ-DI, Health assessment questionnairedisability index; ITT, intent-to-treat; SD, standard deviation; VAS, visual analog scale. 6.7 (7.8) 6.8 (7.5) 7.9 (8.2) 7.8 (8.0) 9.8 (7.3) 9.82 (7.3)
A. HAQ-DI, mean CFB (SD)
CZP
Week 220
6.9 (8.8) 7.7 (7.6) 7.7 (9.1) 8.5 (8.1) 9.7 (9.4) 10.9 (9.3) CFB, change from baseline; CZP, certolizumab pegol; HAQ-DI, Health-Assessment Questionnaire-Disability Index; ITT, intent-to-treat; LOCF, Last Observation Carried Forward; MMRM, Mixed Model Repeated Measures; PBO, Placebo; PtGA, Patient's global assessment of disease activity; SD, Standard Deviation;SF-36 PCS, Short Form-36 Physical Component Summary; Wk, Week.
